Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, GALR1 was also suggested as a tumor suppressor gene that was frequently silenced in head and neck squamous cell carcinoma; moreover, galanin and GALR1 were reported to inhibit human oral cancer cell proliferation.
|
29462183 |
2018 |
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
We generated methylation profiles of GAL and GALR1/2 in tumor samples obtained from 202 patients with head and neck squamous cell carcinoma (HNSCC); these included 43 hypopharynx, 42 larynx, 59 oral cavity, and 58 oropharynx tumor samples.
|
27685843 |
2017 |
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
To determine the prognostic value of GAL, GALR1 and GALR2 methylation status, their associations with various clinical characteristics and patient survival were assessed in HNSCC patient tumors (n = 142).
|
26572146 |
2016 |
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
GALR2 methylation found in 31 of 100 (31.0%) tumor specimens was significantly correlated with the methylation status of both GALR1 and Galanin.
|
24122450 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present study, it was demonstrated that the re‑expression of GALR1 in GALR1 and GALR2‑negative HNSCC cells suppresses tumor cell proliferation.
|
25017118 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The most frequent copy number alterations detected were losses of 18q12.2-qter (including the tumor suppressor genes DCC, SMAD4, and GALR1), 9p21.3 (including the tumor suppressor genes CDKN2A/B), 6q22.1-q23.1, and 8pter-p12.1, and gains of 8q24.3 (including the oncogene MAFA), 11q12.3-q13.2, 3q26.1-q28, 19p13.2-p13.11, and 8q11.1-q12.2 (including the oncogenes LYN, MOS, and PLAG1).
|
23018873 |
2013 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of GalR1 was relatively increased in most, whereas GalR2 was decreased in some tumors.
|
22889491 |
2012 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In head and neck squamous carcinoma cells (HNSCC) with silenced GALR1 and GALR2, we showed that reexpressed GALR1 suppresses tumor cell proliferation via Erk1/2-mediated effects on cdk inhibitors and cyclin D1.
|
19276245 |
2009 |
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
To determine if loss of heterozygosity and hypermethylation might silence the GALR1 gene, promoter methylation status and gene expression were assessed in a large panel of HNSCC cell lines and tumors.
|
19047085 |
2008 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Pharmacological analysis of tumor membrane homogenates with GAL and the specific GAL receptor GalR2 agonist, AR-M1896, revealed that the GAL receptor GalR1 is most likely the receptor responsible for the observed GAL binding in the glioblastomas.
|
12734662 |
2003 |